Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Cetuximab in Solid tumor: NCT07300150 Clinical Landscape Report 2026
16 October 2026
NCT07300150 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Afimkibart in Pediatric Crohn's Disease: NCT07298421 Clinical Landscape Report 2026
16 October 2026
NCT07298421 clinical landscape for Pediatric Crohn's Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RNK08954 in KRAS G12D mutation Solid Tumors: NCT07303465 Clinical Landscape Report 2026
16 October 2026
NCT07303465 clinical landscape for KRAS G12D mutation Solid Tumors: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Amphotericin B in Crohn Disease: NCT07300553 Clinical Landscape Report 2026
16 October 2026
NCT07300553 clinical landscape for Crohn Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HLX-43 in Pancreatic Ductal Adenocarcinoma: NCT07301229 Clinical Landscape Report 2026
16 October 2026
NCT07301229 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Tunlametinib in Pancreatic carcinoma non-resectable: NCT07302841 Clinical Landscape Report 2026
16 October 2026
NCT07302841 clinical landscape for Pancreatic carcinoma non-resectable: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Revefenacin in Pulmonary Disease, Chronic Obstructive: CTRI/2025/12/099782 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/12/099782 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and developm…
9 min read
Ustekinumab in Crohn Disease: NCT07303686 Clinical Landscape Report 2026
16 October 2026
NCT07303686 clinical landscape for Crohn Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AST-3424 in Hepatocellular Carcinoma: NCT07310173 Clinical Landscape Report 2026
16 October 2026
NCT07310173 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VT-5006 in Herpesviridae Infections: NCT07310264 Clinical Landscape Report 2026
16 October 2026
NCT07310264 clinical landscape for Herpesviridae Infections: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Thalidomide in Unresectable Hepatocellular Carcinoma: NCT07309419 Clinical Landscape Report 2026
16 October 2026
NCT07309419 clinical landscape for Unresectable Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Guselkumab in Crohn Disease: NCT07310095 Clinical Landscape Report 2026
16 October 2026
NCT07310095 clinical landscape for Crohn Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.